Insider Selling: Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Insider Sells 2,500 Shares of Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) insider Eric R. Olson sold 2,500 shares of Syros Pharmaceuticals stock in a transaction on Monday, August 7th. The stock was sold at an average price of $23.59, for a total value of $58,975.00. Following the sale, the insider now directly owns 2,500 shares of the company’s stock, valued at $58,975. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Syros Pharmaceuticals, Inc. (NASDAQ SYRS) opened at 20.17 on Friday. The company has a 50 day moving average price of $19.99 and a 200-day moving average price of $15.77. The firm’s market cap is $529.66 million. Syros Pharmaceuticals, Inc. has a 52-week low of $10.22 and a 52-week high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Wednesday, August 9th. The company reported ($0.52) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. On average, analysts expect that Syros Pharmaceuticals, Inc. will post ($2.09) earnings per share for the current fiscal year.

WARNING: This story was reported by BNB Daily and is owned by of BNB Daily. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/syros-pharmaceuticals-inc-nasdaqsyrs-insider-eric-r-olson-sells-2500-shares-updated.html.

Institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System boosted its position in Syros Pharmaceuticals by 131.3% in the second quarter. California State Teachers Retirement System now owns 22,200 shares of the company’s stock valued at $357,000 after buying an additional 12,600 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Syros Pharmaceuticals by 11,253.8% in the second quarter. The Manufacturers Life Insurance Company now owns 10,559 shares of the company’s stock valued at $170,000 after buying an additional 10,466 shares during the period. Redmile Group LLC raised its position in Syros Pharmaceuticals by 2.2% in the second quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after buying an additional 20,520 shares during the period. State Street Corp raised its position in Syros Pharmaceuticals by 176.7% in the second quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after buying an additional 108,250 shares during the period. Finally, ARK Investment Management LLC raised its position in Syros Pharmaceuticals by 114.7% in the second quarter. ARK Investment Management LLC now owns 17,705 shares of the company’s stock valued at $285,000 after buying an additional 9,460 shares during the period. 49.66% of the stock is owned by institutional investors.

SYRS has been the topic of several recent analyst reports. ValuEngine upgraded Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Zacks Investment Research lowered Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Cowen and Company restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. JMP Securities lowered Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 10th. Finally, Wedbush restated an “outperform” rating and issued a $22.84 price target (down from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Syros Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $20.81.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply